SCHEMBL36611

SCHEMBL36611

NC(=O)CC[C@H](NC(=O)OCc1ccccc1)C(=O)NCC(=O)O

nearest known ligand 0.65

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.61
CTSS P25774 5/20 0.55
CTSL P07711 4/20 0.55
MME P08473 2/20 0.54
ECE1 P42892 2/20 0.54
CTSK P43235 5/20 0.53
CTSB P07858 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8496964 1.00 SMN1; SMN2 (0.61) SMN1; SMN2CTSSCTSLMMEECE1
Hydroxyamine SCHEMBL9197242 0.99 SMN1; SMN2 (0.60) SMN1; SMN2CTSSCTSLMMEECE1
SCHEMBL9228661 0.98 SMN1; SMN2 (0.59) SMN1; SMN2CTSSCTSLMMEECE1
SCHEMBL9228658 0.98 SMN1; SMN2 (0.59) SMN1; SMN2CTSSCTSLMMEECE1
SCHEMBL29437121 0.94 SMN1; SMN2 (0.62) SMN1; SMN2CTSSCTSLMMEECE1
SCHEMBL1122463 0.91 CTSS (0.58) CTSSCTSLMMEECE1CTSK
SCHEMBL13884485 0.91 CTSS (0.58) CTSSCTSLMMEECE1CTSK
SCHEMBL14433709 0.91 CTSS (0.58) CTSSCTSLMMEECE1CTSK
SCHEMBL10385461 0.90 SMN1; SMN2 (0.60) SMN1; SMN2CTSSCTSLMMEECE1
SCHEMBL10385459 0.90 SMN1; SMN2 (0.60) SMN1; SMN2CTSSCTSLMMEECE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 607 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117165149-B Epoxy zinc-rich primer containing graphene-conductive nickel material and preparation method thereof 成都虹润制漆有限公司 2025-04-11 CN claimed
CN-117165149-A Epoxy zinc-rich primer containing graphene-conductive nickel material and preparation method thereof 成都虹润制漆有限公司 2023-12-05 CN claimed
CN-114634966-A Enzyme activity detection method of protein glutamyl enzyme and application thereof 武汉新华扬生物股份有限公司 2022-06-17 CN claimed
EP-0379606-B2 Novel transglutaminase AJINOMOTO KK (JP) 1999-07-28 EP claimed
EP-0555046-B1 Method for determination of calcium ORIENTAL YEAST CO LTD (JP) 1997-07-30 EP claimed
US-5618684-A CALCIUM ACTIVATED TRANSGLUTAMINASE ACTS ON SUBSTRATE TO GENERATE AMMONIA; CORRELATING AMOUNT OF AMMONIA GENERATED WITH AN AMOUNT OF CALCIUM ORIENTAL YEAST CO., LTD. (JP) 1997-04-08 US claimed
JP-7075569-A None JP disclosed
US-20260137106-A1 PROCESS FOR PREPARING A LIQUID OAT BASE OATLY AB (SE) 2026-05-21 US disclosed
US-20260139068-A1 ANTI-CD73 ANTIBODIES, CONJUGATES, AND METHODS OF USE EISAI R&D MAN CO LTD (JP) 2026-05-21 US disclosed
US-12630807-B2 Modified transglutaminase AMANO ENZYME INC. (JP) 2026-05-19 US disclosed
EP-4739141-A1 METHOD FOR OBTAINING A DAIRY ALTERNATIVE FOOD PRODUCT WITH IMPROVED FOAMING Novozymes A/S (DK) 2026-05-13 EP disclosed
US-12616231-B2 Heat coagulation gel strength regulating agent for egg white protein AMANO ENZYME INC. (JP) 2026-05-05 US disclosed
EP-4729611-A1 LIQUID ENZYME PREPARATION Amano Enzyme Inc. (JP) 2026-04-22 EP disclosed
US-5252469-A Culturing the microorganism in the absence of calcium ion AMANO PHARMACEUTICAL CO., LTD. (JP) 1993-10-12 US disclosed
EP-0555046-A1 Method for determination of calcium ORIENTAL YEAST CO., LTD. (JP) 1993-08-11 EP disclosed
US-5156956-A Derived from microorganism; catalyzes protein gelation in absence of calcium AJINOMOTO CO., INC. (JP) 1992-10-20 US disclosed
US-5055310-A Reacting soy milk with solidifying agent and transglutaminase enzyme as catalyst AJINOMOTO CO., INC. (JP) 1991-10-08 US disclosed
US-4970297-A CONTAINING ISOXAZOLE RING SYNTEX (U.S.A.) INC. (US) 1990-11-13 US disclosed
EP-0379606-A1 Novel transglutaminase AJINOMOTO CO., INC. (JP) 1990-08-01 EP disclosed
JP-H00775569-A 0001-01-01 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260139068-A1 ANTI-CD73 ANTIBODIES, CONJUGATES, AND METHODS OF USE ENTPD3, ENTPD1, ENTPD2 SMN1; SMN2 3883/4885CTSS 3758/4885CTSL 4056/4885
US-12616231-B2 Heat coagulation gel strength regulating agent for egg white protein TGM2, TGM3, TGM1 SMN1; SMN2 4192/4885CTSS 881/4885CTSL 1131/4885
US-20260137106-A1 PROCESS FOR PREPARING A LIQUID OAT BASE GYS1, OAT, GYS2 SMN1; SMN2 3472/4885CTSS 114/4885CTSL 104/4885
US-12630807-B2 Modified transglutaminase TGM2, GLUL, TGM1 SMN1; SMN2 2866/4885CTSS 2090/4885CTSL 1798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.